BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29658031)

  • 1. Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring.
    Kim CJ; Park J; Sunkara V; Kim TH; Lee Y; Lee K; Kim MH; Cho YK
    Lab Chip; 2018 May; 18(9):1320-1329. PubMed ID: 29658031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure.
    Lee H; Jeon S; Seo JS; Goh SH; Han JY; Cho Y
    Biomaterials; 2016 Sep; 101():251-7. PubMed ID: 27294542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.
    Gorgannezhad L; Umer M; Islam MN; Nguyen NT; Shiddiky MJA
    Lab Chip; 2018 Apr; 18(8):1174-1196. PubMed ID: 29569666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
    Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
    J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis increases sensitivity to detect cancer mutations in plasma.
    Marques JF; Junqueira-Neto S; Pinheiro J; Machado JC; Costa JL
    Eur J Cancer; 2020 Mar; 127():130-138. PubMed ID: 32007713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
    Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
    Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
    Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA for personalized lung cancer monitoring.
    Fiala C; Diamandis EP
    BMC Med; 2017 Aug; 15(1):157. PubMed ID: 28814291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.
    Chen K; Zhao H; Yang F; Hui B; Wang T; Wang LT; Shi Y; Wang J
    BMJ Open; 2018 Feb; 8(2):e019012. PubMed ID: 29437753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
    Isobe K; Hata Y; Kobayashi K; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Takagi K; Homma S
    Anticancer Res; 2012 Aug; 32(8):3339-44. PubMed ID: 22843912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
    Dietz S; Schirmer U; Mercé C; von Bubnoff N; Dahl E; Meister M; Muley T; Thomas M; Sültmann H
    PLoS One; 2016; 11(8):e0161012. PubMed ID: 27529345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
    Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
    Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.